The U.S. Food and Drug Aministration has approved olezarsen, a first-in-class drug to reduce triglycerides in adults with familial chylomicronemia syndrome. Olezarsen is an antisense oligonucleotide-directed inhibitor of apolipoprotein C-III messenger ribonucleic acid.

PHARMACOLOGY UPDATE
Olezarsen Injection (Tryngolza)
February 28, 2025